Skip to content
OpenCapital
Get started

TriSalus Life Sciences, Inc. TLSI Class of Warrant or Right, Outstanding

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%—
Debt / equity2.6×—
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s class of warrant or right, outstanding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s class of warrant or right, outstanding?
TriSalus Life Sciences, Inc. (TLSI) reported class of warrant or right, outstanding of $7.4M in Q1 2026.
How has TriSalus Life Sciences, Inc.'s class of warrant or right, outstanding changed year-over-year?
TriSalus Life Sciences, Inc.'s class of warrant or right, outstanding decreased by 0.0% year-over-year, from $7.4M to $7.4M.
What is the long-term trend for TriSalus Life Sciences, Inc.'s class of warrant or right, outstanding?
Over 3 years (2022 to 2025), TriSalus Life Sciences, Inc.'s class of warrant or right, outstanding has grown at a 37.1% compound annual growth rate (CAGR), from $2.87M to $7.4M.